Search

Your search keyword '"Molinier L"' showing total 272 results
Start Over Author "Molinier L"
272 results on '"Molinier L"'

2. MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA.

Author

Vellas, B, Carrie, I, Gillette-Guyonnet, S, Touchon, J, Dantoine, T, Dartigues, JF, Cuffi, MN, Bordes, S, Gasnier, Y, Robert, P, Bories, L, Rouaud, O, Desclaux, F, Sudres, K, Bonnefoy, M, Pesce, A, Dufouil, C, Lehericy, S, Chupin, M, Mangin, JF, Payoux, P, Adel, D, Legrand, P, Catheline, D, Kanony, C, Zaim, M, Molinier, L, Costa, N, Delrieu, J, Voisin, T, Faisant, C, Lala, F, Nourhashémi, F, Rolland, Y, Van Kan, G Abellan, Dupuy, C, Cantet, C, Cestac, P, Belleville, S, Willis, S, Cesari, M, Weiner, MW, Soto, ME, Ousset, PJ, and Andrieu, S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Alzheimer's Disease, Clinical Research, Neurodegenerative, Brain Disorders, Clinical Trials and Supportive Activities, Aging, Prevention, Behavioral and Social Science, Neurosciences, Nutrition, Acquired Cognitive Impairment, Dementia, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Complementary and Integrative Health, Neurological, Alzheimer’s disease, Multidomain intervention, Omega-3 fatty acids, Biological psychology, Cognitive and computational psychology
Abstract

ObjectiveThe Multidomain Alzheimer Preventive Trial (MAPT study) was designed to assess the efficacy of isolated supplementation with omega-3 fatty acid, an isolated multidomain intervention (consisting of nutritional counseling, physical exercise, cognitive stimulation) or a combination of the two interventions on the change of cognitive functions in frail subjects aged 70 years and older for a period of 3 years. Ancillary neuroimaging studies were additionally implemented to evaluate the impact of interventions on cerebral metabolism (FDG PET scans) and atrophy rate (MRIs), as well as brain amyloïd deposit (AV45 PET scans).Design patients1680 subjects (mean age: 75.3 years; female: 64.8 %), enrolled by 13 memory clinics, were randomized into one of the following four groups: omega-3 supplementation alone, multidomain intervention alone, omega-3 plus multidomain intervention, or placebo. Participants underwent cognitive, functional and biological assessments at M6, M12, M24 and M36 visits. The primary endpoint is a change of memory function at 3 years, as assessed by the Free and Cued Selective Reminding test. All participants will be followed for 2 additional years after the 3-years intervention (MAPT PLUS extension study).Interventions1/Omega-3 supplementation: two soft capsules daily as a single dose, containing a total of 400 mg docosahexaenoic acid (DHA), i.e., 800 mg docosahexaenoic acid per day, for 3 years. 2/ Multidomain intervention: collective training sessions conducted in small groups (6-8 participants) in twelve 120-minute sessions over the first 2 months (two sessions a week for the first month, and one session a week the second month) then a 60-minute session per month in the following three areas: nutrition, physical activity, and cognition until the end of the 3 years. In addition to the collective sessions, individualized preventive outpatient visits exploring possible risk factors for cognitive decline are performed at baseline, M12 and M24.Baseline populationFor cognition, the mean MMSE at baseline was 28.1 (± 1.6). About 58% and 42% of participants had a CDR score equal to 0 and 0.5, respectively. Regarding mobility status, 200 (11.9%) had a 4-m gait speed lower or equal to 0.8 m/s. According to the Fried criteria, 673 (42.1%) participants were considered pre frail, and 51 (3.2%) frail. The red blood cell DHA content was 26.1 ± 8.1 µg/g. Five hundred and three participants underwent baseline MRI. AV45 PET scans were performed in 271 individuals and preliminary results showed that 38.0% had a cortical SUVR > 1.17, which gave an indication of significant brain amyloïd deposit. DISCUSSION: The MAPT trial is presently the first largest and longest multidomain preventive trial relevant to cognitive decline in older adults with subjective memory complaints. The multidomain intervention designed for the MAPT trial is likely to be easily implemented within the general population.

Published
2014

8. P073 - Mise en œuvre des méthodes d’« Optimal Matching » et de Classification ascendante hiérarchique pour l’étude du parcours de soins de patients âgés hospitalisés après une chute

Author

Mounié, M., primary, Fabre, D., additional, Rapp, T., additional, Blain, H., additional, Rolland, Y., additional, Tchalla, A., additional, Carcaillon-Bentata, L., additional, Nathalie, B., additional, Assous, L., additional, Apparitio, S., additional, Caby, D., additional, Reina, N., additional, Andre, L., additional, Demeulemeester, R., additional, Molinier, L., additional, and Costa, N., additional

Published
2023
Full Text
View/download PDF

20. PND44 EVALUATION OF THE EFFICIENCY OF FOUR PREVENTION STRATEGIES IN ALZHEIMER'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT) STUDY

Author

Costa, N., primary, Mounié, M., additional, Pagès, A., additional, Guyonnet, S., additional, Carrié, I., additional, Coley, N., additional, Cantet, C., additional, Rapp, T., additional, Derumeaux-Burel, H., additional, Andrieu, S., additional, Vellas, B., additional, and Molinier, L., additional

Published
2020
Full Text
View/download PDF

21. PDB21 EVALUATION OF THE ONE-YEAR EFFICIENCY OF THE EDUC@DOM TELEMONITORING AND TELE-EDUCATION PROGRAM FOR TYPE 2 DIABETIC PATIENTS

Author

Mounié, M., primary, Costa, N., additional, Martini, J., additional, Latorre, C., additional, Buisson, J.C., additional, Delaunay, J., additional, Schirrbonnans, S., additional, Taoui, S., additional, Lepage, B., additional, Colineaux, H., additional, Gourdy, P., additional, Hanaire, H., additional, Molinier, L., additional, and Turnin, M.C., additional

Published
2020
Full Text
View/download PDF

23. Premiers résultats du protocole multicentrique EDUC@DOM de télésurveillance du diabète de type 2

Author

Turnin, M.C., primary, Martini, J., additional, Chauchard, M.C., additional, Rodier, M., additional, Benhamou, P.Y., additional, Chaillous, L., additional, Thivolet, C., additional, Penfornis, A., additional, Schirr-Bonnans, S., additional, Taoui, S., additional, Delaunay, J., additional, Costa, N., additional, Lepage, B., additional, Molinier, L., additional, and Hanaire, H., additional

Published
2018
Full Text
View/download PDF

28. MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA

Author

Vellas, B, Carrie, I, Gillette-Guyonnet, S, Touchon, J, Dantoine, T, Dartigues, JF, Cuffi, MN, Bordes, S, Gasnier, Y, Robert, P, Bories, L, Rouaud, O, Desclaux, F, Sudres, K, Bonnefoy, M, Pesce, A, Dufouil, C, Lehericy, S, Chupin, M, Mangin, JF, Payoux, P, Adel, D, Legrand, P, Catheline, D, Kanony, C, Zaim, M, Molinier, L, Costa, N, Delrieu, J, Voisin, T, Faisant, C, Lala, F, Nourhashémi, F, Rolland, Y, Van Kan, G Abellan, Dupuy, C, Cantet, C, Cestac, P, Belleville, S, Willis, S, Cesari, M, Weiner, MW, Soto, ME, Ousset, PJ, and Andrieu, S

Subjects
Aging, Multidomain intervention, Prevention, Clinical Trials and Supportive Activities, Neurosciences, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Neurodegenerative, Alzheimer's Disease, Article, Brain Disorders, Clinical Research, Complementary and Integrative Health, Behavioral and Social Science, Neurological, Omega-3 fatty acids, Acquired Cognitive Impairment, Dementia, Alzheimer’s disease, Nutrition
Abstract

ObjectiveThe Multidomain Alzheimer Preventive Trial (MAPT study) was designed to assess the efficacy of isolated supplementation with omega-3 fatty acid, an isolated multidomain intervention (consisting of nutritional counseling, physical exercise, cognitive stimulation) or a combination of the two interventions on the change of cognitive functions in frail subjects aged 70 years and older for a period of 3 years. Ancillary neuroimaging studies were additionally implemented to evaluate the impact of interventions on cerebral metabolism (FDG PET scans) and atrophy rate (MRIs), as well as brain amyloïd deposit (AV45 PET scans).Design patients1680 subjects (mean age: 75.3 years; female: 64.8 %), enrolled by 13 memory clinics, were randomized into one of the following four groups: omega-3 supplementation alone, multidomain intervention alone, omega-3 plus multidomain intervention, or placebo. Participants underwent cognitive, functional and biological assessments at M6, M12, M24 and M36 visits. The primary endpoint is a change of memory function at 3 years, as assessed by the Free and Cued Selective Reminding test. All participants will be followed for 2 additional years after the 3-years intervention (MAPT PLUS extension study).Interventions1/Omega-3 supplementation: two soft capsules daily as a single dose, containing a total of 400 mg docosahexaenoic acid (DHA), i.e., 800 mg docosahexaenoic acid per day, for 3 years. 2/ Multidomain intervention: collective training sessions conducted in small groups (6-8 participants) in twelve 120-minute sessions over the first 2 months (two sessions a week for the first month, and one session a week the second month) then a 60-minute session per month in the following three areas: nutrition, physical activity, and cognition until the end of the 3 years. In addition to the collective sessions, individualized preventive outpatient visits exploring possible risk factors for cognitive decline are performed at baseline, M12 and M24.Baseline populationFor cognition, the mean MMSE at baseline was 28.1 (± 1.6). About 58% and 42% of participants had a CDR score equal to 0 and 0.5, respectively. Regarding mobility status, 200 (11.9%) had a 4-m gait speed lower or equal to 0.8 m/s. According to the Fried criteria, 673 (42.1%) participants were considered pre frail, and 51 (3.2%) frail. The red blood cell DHA content was 26.1 ± 8.1 µg/g. Five hundred and three participants underwent baseline MRI. AV45 PET scans were performed in 271 individuals and preliminary results showed that 38.0% had a cortical SUVR > 1.17, which gave an indication of significant brain amyloïd deposit. DISCUSSION: The MAPT trial is presently the first largest and longest multidomain preventive trial relevant to cognitive decline in older adults with subjective memory complaints. The multidomain intervention designed for the MAPT trial is likely to be easily implemented within the general population.

Published
2015

29. [Stage IV NSCLC. Economic analysis in lung cancers]

Author

Vergnenegre, A., Atsou, K., Molinier, L., christos chouaid, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), SCHILLER J, K Atsou, Molinier L, C Chouaïd ., and Annesi-Maesano, Isabella

Subjects
MESH: Humans, Lung Neoplasms, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Carcinoma, Non-Small-Cell Lung, Costs and Cost Analysis, Humans, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Neoplasm Staging, MESH: Costs and Cost Analysis, health care economics and organizations, MESH: Carcinoma, Non-Small-Cell Lung, MESH: Lung Neoplasms, Neoplasm Staging
Abstract

International audience; OBJECTIVE: To explain the help of economic analyses in the understanding of lung cancer (LC) management with a description of the quality of selected papers. METHODS: In the first part, quality criteria of economic analyses are depicted with the key words for the literature selection. RESULTS: The global costs of LC through literature review are depicted; then, in a second part, the costs of each stage of the disease. Finally, costs of chemotherapeutic drugs and target molecules are also discussed. CONCLUSION: Economic analyses are unavoidable to assess the burden of the disease but also the cost of each management strategy for LC.

Published
2008

35. [The cost components of the management strategies for lung cancer in France]

Author

Vergnenègre, A., Molinier, L., Combescure, C., Daurès, J.-P., Housset, B., Chouaid, C., Annesi-Maesano, Isabella, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), SCHILLER A, Molinier L, C Combescure, JP Daurès, B Housset, and C Chouaid

Subjects
MESH: Aged, MESH: Decision Trees, MESH: Humans, MESH: Middle Aged, Lung Neoplasms, Decision Trees, MESH: Retrospective Studies, Middle Aged, MESH: Costs and Cost Analysis, MESH: Lung Neoplasms, MESH: France, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Costs and Cost Analysis, Humans, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, health care economics and organizations, Aged, Retrospective Studies
Abstract

International audience; INTRODUCTION: To evaluate the average cost of therapeutic strategies for the management of lung cancer in relation to histological type and diagnostic staging and of the individual components of the management strategy. METHODS: Samples were taken between 1 September 1998 and 30 June 1999 from centres with sufficient numbers of lung cancer (LC) cases. All events over an 18 Month period were collected from a retrospective analysis of the records. A Markov model was constructed based on decision branches for localised and diffuse small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Several components of management were identified: first line treatment, second line treatment, observation, terminal care and death. RESULTS: The average cost of LC was 22,006 Euro (10,631-36,296) for one year and 25,643 Euro (10,631-46,191) for two years. For SCLC the average annual costs were 22,420 Euro for diffuse disease and 27,098 for localised disease. For NSCLC the totals ranged from 19,543 Euro for inoperable stage I and II tumours to 39,424 for operable tumours. The cost for stage IV tumours was 24,383 Euro. The cost components over two Years varied according to the tumour type. The cost of diagnosis ranged from 6-14%, the cost of management and of terminal care from 33-45% of the total. Analyses of sensitivity confirmed that whatever the histological type or diagnostic staging the percentage of patients initially treated actively (that is to say not by palliative care) had the greatest effect on the total cost, greater than the costs of terminal care and of two courses of chemotherapy. CONCLUSIONS: This model has allowed for the first time the calculation of the contributions of the different therapeutic components to the total cost of the management of lung cancer in France. In the future it will allow analysis of the economic impact of new methods of treatment.

Published
2004

38. Economic analyses and lung cancer

Author

Vergnenegre, A., Molinier, L., christos chouaid, Annesi-Maesano, Isabella, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), SCHILLER A, Molinier L, and C Chouaïd .

Subjects
Male, Canada, MESH: Humans, Lung Neoplasms, Cost-Benefit Analysis, MESH: Health Care Costs, MESH: Carcinoma, Small Cell, Health Care Costs, MESH: Cost of Illness, MESH: Male, MESH: Lung Neoplasms, MESH: France, Cost of Illness, MESH: Canada, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Carcinoma, Non-Small-Cell Lung, Humans, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, France, Carcinoma, Small Cell, MESH: Female, MESH: Carcinoma, Non-Small-Cell Lung, MESH: Cost-Benefit Analysis
Abstract

International audience; The economic assessment of treatments or medical strategies has been the subject of an increasing number of publications. The elevated costs and relative lack of efficacy of many treatments of chronic diseases such as lung cancer are an added impetus to such analyses. In the first part of this review, we summarise the theoretical basis of economic assessment, the tools available and the limitations of these methods. In the second part, we examine their application to the treatment of lung cancer. We discuss the evaluation of the cost of these cancers to society, economic assessment of new chemotherapeutic drugs, and the place of cost-effectiveness analysis in randomized trials. In the last part, we outline the interest and future of such considerations for clinicians. These methods, which provide complementary data for clinicians when making decisions on therapeutic options, will be adopted more widely in coming years.

Published
2002

39. Surgical site infection after valvular or coronary artery bypass surgery: 2008–2011 French SSI national ISO-RAISIN surveillance

Author

Cossin, S., primary, Malavaud, S., additional, Jarno, P., additional, Giard, M., additional, L'Hériteau, F., additional, Simon, L., additional, Bieler, L., additional, Molinier, L., additional, Marcheix, B., additional, Venier, A.-G., additional, Ali-Brandmeyer, O., additional, Neels, C., additional, Aupée, M., additional, Perennec, M., additional, Astagneau, P., additional, Daniel, F., additional, Campion, C., additional, Bernet, C., additional, Caillat-Vallet, E., additional, Bervas, C., additional, Reyreaud, E., additional, Baillet, P., additional, Costa, Y., additional, Jost, J.-L., additional, Merle, V., additional, Merlo, L., additional, Seguier, J.-C., additional, Bruyere, F., additional, Thiolet, J.-M., additional, and Barquin-Guichard, S., additional

Published
2015
Full Text
View/download PDF

42. Cost of care of Agitation and Agression associated to dementia in 8 European Countries: results from the Right Time Place Care (RTPC) study

Author

Costa, N., primary, Wübker, A., additional, Binot, I., additional, Demauleon, A., additional, Zwakhalen, S.M., additional, Challis, D., additional, Stolt, M., additional, Stephan, A., additional, Zabalegui, A., additional, Saks, K., additional, Vellas, B., additional, Molinier, L., additional, Sauerland, D., additional, and Soto Martin, M.E., additional

Published
2015
Full Text
View/download PDF

47. Integrating complete lower limb verous ultrasound in diagnostic strategies for pulmatory embolis: a cost-effectivenes analysis

Author

Hélias, A., Molinier, L., Bauvin, E., Elias, M., Duru, Gérard, Colin, C., SI LIRIS, Équipe gestionnaire des publications, Laboratoire d'InfoRmatique en Image et Systèmes d'information (LIRIS), Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-École Centrale de Lyon (ECL), and Université de Lyon-Université Lumière - Lyon 2 (UL2)

Subjects
[INFO]Computer Science [cs], [INFO] Computer Science [cs], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results